INDOUS

Indo US Bio-Tech Share Price

 

 

Start SIP in INDOUS

Start SIP

Performance

  • Low
  • ₹142
  • High
  • ₹151
  • 52 Week Low
  • ₹105
  • 52 Week High
  • ₹224
  • Open Price₹144
  • Previous Close₹146
  • Volume106,795
  • 50 DMA₹128.62
  • 100 DMA₹131.82
  • 200 DMA₹150.75

Investment Returns

  • Over 1 Month + 35.61%
  • Over 3 Month + 22.81%
  • Over 6 Month -0.07%
  • Over 1 Year -31.04%

Smart Investing Starts Here Start SIP with Indo US Bio-Tech for Steady Growth!

Invest Now

Indo US Bio-Tech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 20.4
  • PEG Ratio
  • 1.5
  • Market Cap Cr
  • 302
  • P/B Ratio
  • 3.5
  • Average True Range
  • 7.95
  • EPS
  • 7.4
  • Dividend Yield
  • 0
  • MACD Signal
  • 4.12
  • RSI
  • 71.39
  • MFI
  • 77.02

Indo US Bio-Tech Financials

Indo US Bio-Tech Technicals

EMA & SMA

Current Price
₹150.72
+ 4.48 (3.06%)
pointer
  • Bearish Moving Average 1
  • Bullish Moving Average 15
  • 20 Day
  • ₹133.56
  • 50 Day
  • ₹128.62
  • 100 Day
  • ₹131.82
  • 200 Day
  • ₹150.75

Resistance and Support

147.84 Pivot Speed
  • R3 163.02
  • R2 157.00
  • R1 153.86
  • S1 144.70
  • S2 138.68
  • S3 135.54

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Indo Us Bio-Tech has an operating revenue of Rs. 117.80 Cr. on a trailing 12-month basis. An annual revenue growth of 42% is outstanding, Pre-tax margin of 16% is great, ROE of 20% is exceptional. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 200DMA and around 18% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 53 which is a POOR score indicating inconsistency in earnings, a RS Rating of 64 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 96 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Indo US Bio-Tech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-21 Quarterly Results
2025-11-14 Quarterly Results
2025-10-14 Others Inter-alia, to consider 1. Re-appointment of M/s. Gautam N Associates as a Statutory Auditors of the Company. 2. Approve Notice of Postal Ballot. 3. Other business matters. per share(2.5%)Interim Dividend
2025-08-12 Quarterly Results
2025-05-26 Audited Results
Date Purpose Remarks
2024-12-03 INTERIM Rs.0.25 per share(2.5%)Interim Dividend
2021-10-29 INTERIM Rs.0.25 per share(2.5%)Interim Dividend
View Indo US Bio-Tech Dividend History Arrow
Date Purpose Remarks
2023-08-29 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.
2021-11-30 Bonus Rs.0.00 issue in the ratio of 1:5 of Rs. 10/-.

Indo US Bio-Tech F&O

Indo US Bio-Tech Shareholding Pattern

70.17%
0%
23.69%
6.14%

About Indo US Bio-Tech

  • NSE Symbol
  • INDOUS
  • BSE Symbol
  • 541304
  • Managing Director
  • Mr. Jagdish Ajudia
  • ISIN
  • INE250Z01010

Similar Stocks to Indo US Bio-Tech

Indo US Bio-Tech FAQs

Indo US Bio-Tech share price is ₹150 As on 22 February, 2026 | 19:05

The Market Cap of Indo US Bio-Tech is ₹302.2 Cr As on 22 February, 2026 | 19:05

The P/E ratio of Indo US Bio-Tech is 20.4 As on 22 February, 2026 | 19:05

The PB ratio of Indo US Bio-Tech is 3.5 As on 22 February, 2026 | 19:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23